Benefits of drug-eluting stents: a meta-analysis
This article has no abstract so we have provided the first paragraph of the full text.
Drug-eluting stents (DES) are designed to reduce the extent of in-stent restenosis following percutaneous coronary intervention (PCI), via the controlled elution of an antimitotic drug such as sirolimus or paclitaxel. Clinical trials investigating the benefits of DES over bare-metal stents (BMS), however, have been insufficiently powered to generate useful data on rates of mortality, myocardial infarction (MI) or other complications. Babapulle and colleagues have performed a meta-analysis of randomized trials in order to provide this information.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
